Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Watson Pharma rolls out generic Amrix
Amrix extended-release capsule is a muscle relaxant and works in parts of the brain and nervous system to help reduce muscle spasms. Amrix is approved for use along
Amrix extended-release capsule is a muscle relaxant and works in parts of the brain and nervous system to help reduce muscle spasms. Amrix is approved for use along
Bromfenac Ophthalmic Solution, 0.09% is the generic version of ISTA’s Xibrom Ophthalmic Solution, 0.09%. Xibrom is indicated for the treatment of postoperative inflammation and the reduction of ocular
Developed by BioAlliance Pharma, Loramyc is a mucoadhesive gingival tablet containing miconazole administered once-a-day over 7 to 14 days. Additionally, Therabel has made a fully dedicated team and
The decrease of $160,000 in revenue was due primarily to a decrease in Aphthasol product sales during the first quarter of 2011. ULURU has reported a net loss
Synexus has delivered the targeted number of patients within the agreed timelines. Synexus chief executive Christophe Berthoux said the Synexus model works particularly well with companies like Creabilis
MWV said its preservative-free pump solutions offer a five-fold mechanical protection system that assures germ-free pump dosing to the patient while providing shelf life similar to traditional formulations.
The company has reported a net income of $2.24m, or $0.08 per diluted share, compared to net income of $4.93m or $0.18 per diluted share, for the same
CPI-300 is a high strength of Bupropion Hydrochloride (HCl), the active ingredient in Wellbutrin XL. The company’s new submission addresses the two main issues identified by the FDA
VICTRELIS is a direct acting antiviral (DAA) agent that interferes with the ability of the hepatitis C virus to replicate by inhibiting a key viral enzyme (NS3/4A serine
Sinovac’s net loss was $3.66m for the first quarter 2011, or $0.05 loss per diluted share, compared to net loss of $1.21m, or $0.01 loss per diluted share,